Trial Outcomes & Findings for Study of Weekly Radiotherapy for Bladder Cancer (NCT NCT01810757)
NCT ID: NCT01810757
Last Updated: 2026-01-15
Results Overview
Non-GU CTCAE G3+ treatment-related toxicity occurring within the first 3 months of radiotherapy completing
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
65 participants
Primary outcome timeframe
12 weeks from completion of radiotherapy
Results posted on
2026-01-15
Participant Flow
Participant milestones
| Measure |
Standard Planning
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
Overall Study
STARTED
|
32
|
33
|
|
Overall Study
COMPLETED
|
32
|
33
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Study of Weekly Radiotherapy for Bladder Cancer
Baseline characteristics by cohort
| Measure |
Standard Planning
n=32 Participants
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
n=33 Participants
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
Total
n=65 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Multiple tumours
Yes
|
6 Participants
n=9 Participants
|
7 Participants
n=6 Participants
|
13 Participants
n=9 Participants
|
|
Age, Continuous
|
84.8 years
n=9 Participants
|
84.1 years
n=6 Participants
|
84.5 years
n=9 Participants
|
|
Sex: Female, Male
Female
|
8 Participants
n=9 Participants
|
13 Participants
n=6 Participants
|
21 Participants
n=9 Participants
|
|
Sex: Female, Male
Male
|
24 Participants
n=9 Participants
|
20 Participants
n=6 Participants
|
44 Participants
n=9 Participants
|
|
Region of Enrollment
United Kingdom
|
32 participants
n=9 Participants
|
33 participants
n=6 Participants
|
65 participants
n=9 Participants
|
|
Extent of resection
Biopsy
|
10 Participants
n=9 Participants
|
10 Participants
n=6 Participants
|
20 Participants
n=9 Participants
|
|
Extent of resection
Partial resection
|
10 Participants
n=9 Participants
|
13 Participants
n=6 Participants
|
23 Participants
n=9 Participants
|
|
Extent of resection
Full resection
|
11 Participants
n=9 Participants
|
9 Participants
n=6 Participants
|
20 Participants
n=9 Participants
|
|
Extent of resection
Unobtainable
|
1 Participants
n=9 Participants
|
1 Participants
n=6 Participants
|
2 Participants
n=9 Participants
|
|
Multiple tumours
No
|
26 Participants
n=9 Participants
|
26 Participants
n=6 Participants
|
52 Participants
n=9 Participants
|
|
Histological tumour type
Urothelial
|
31 Participants
n=9 Participants
|
32 Participants
n=6 Participants
|
63 Participants
n=9 Participants
|
|
Histological tumour type
Non-urothelial
|
1 Participants
n=9 Participants
|
1 Participants
n=6 Participants
|
2 Participants
n=9 Participants
|
|
Grade
Grade 1
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Grade
Grade 2
|
1 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=9 Participants
|
|
Grade
Grade 3
|
31 Participants
n=9 Participants
|
33 Participants
n=6 Participants
|
64 Participants
n=9 Participants
|
|
Carcinoma in situ (CIS) present
Yes
|
9 Participants
n=9 Participants
|
11 Participants
n=6 Participants
|
20 Participants
n=9 Participants
|
|
Carcinoma in situ (CIS) present
No
|
22 Participants
n=9 Participants
|
22 Participants
n=6 Participants
|
44 Participants
n=9 Participants
|
|
Carcinoma in situ (CIS) present
Unobtainable
|
1 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=9 Participants
|
|
Clinical stage
T1
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Clinical stage
T2
|
24 Participants
n=9 Participants
|
21 Participants
n=6 Participants
|
45 Participants
n=9 Participants
|
|
Clinical stage
T3a
|
1 Participants
n=9 Participants
|
5 Participants
n=6 Participants
|
6 Participants
n=9 Participants
|
|
Clinical stage
T3b
|
5 Participants
n=9 Participants
|
5 Participants
n=6 Participants
|
10 Participants
n=9 Participants
|
|
Clinical stage
T4a
|
2 Participants
n=9 Participants
|
2 Participants
n=6 Participants
|
4 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
5
|
1 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
6
|
14 Participants
n=9 Participants
|
13 Participants
n=6 Participants
|
27 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
7
|
11 Participants
n=9 Participants
|
5 Participants
n=6 Participants
|
16 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
8
|
4 Participants
n=9 Participants
|
6 Participants
n=6 Participants
|
10 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
9
|
2 Participants
n=9 Participants
|
8 Participants
n=6 Participants
|
10 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
10
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=9 Participants
|
|
Age adjusted Charlson Comorbidity index score
11
|
0 Participants
n=9 Participants
|
1 Participants
n=6 Participants
|
1 Participants
n=9 Participants
|
PRIMARY outcome
Timeframe: 12 weeks from completion of radiotherapyPopulation: Evaluable patient population: This population contains all randomised patients who have received at least one fraction of radiotherapy and are evaluable for the primary endpoint of acute toxicity (i.e. toxicity reported up to 3 months post radiotherapy). Patients had been reviewed for evaluability by the independent Trial steering committee (TSC) blinded to planning method and the TSC's view on evaluability for the primary endpoint has been used to define the evaluable patient population.
Non-GU CTCAE G3+ treatment-related toxicity occurring within the first 3 months of radiotherapy completing
Outcome measures
| Measure |
Standard Planning
n=30 Participants
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
n=33 Participants
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
Proportion of Patients Experiencing Severe Acute Non-genitourinary Side Effects Following Radiotherapy.
|
4 Participants
|
2 Participants
|
SECONDARY outcome
Timeframe: 3 monthsPopulation: Including only those who had an assessment at 3 months
Presence of cancer in the bladder 3 months after treatment. Presented as the proportion of all patients regardless of treatment allocation (standard and adaptive combined) having evidence of residual tumour.
Outcome measures
| Measure |
Standard Planning
n=23 Participants
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
n=25 Participants
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
Local Disease Control Rate
|
17 Participants
|
22 Participants
|
SECONDARY outcome
Timeframe: Event-free survival estimates at 12 months and 24 months are reported.Population: Intention to treat population. It was pre-planned in the SAP to combine the two treatment arms together because there is insufficient statistical power to detect clinically meaningful differences.
From randomisation to a maximum follow-up of 30 months. It was pre-planned in the SAP to combine the two treatment arms together because there is insufficient statistical power to detect clinically meaningful differences.
Outcome measures
| Measure |
Standard Planning
n=65 Participants
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
Time to Local Disease Progression
KM 12 months
|
71.7 percentage event-free
Interval 55.9 to 82.6
|
—
|
|
Time to Local Disease Progression
KM 24 months
|
47.3 percentage event-free
Interval 29.6 to 63.1
|
—
|
SECONDARY outcome
Timeframe: Event-free survival estimates at 12 months and 24months are reported.Population: Intention to treat population. It was pre-planned in the SAP to combine the two treatment arms together because there is insufficient statistical power to detect clinically meaningful differences.
From randomisation to maximum follow-up of 56 months. It was pre-planned in the SAP to combine the two treatment arms together because there is insufficient statistical power to detect clinically meaningful differences.
Outcome measures
| Measure |
Standard Planning
n=65 Participants
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
Overall Survival
KM 12 months
|
61.5 percentage surviving
Interval 48.6 to 72.1
|
—
|
|
Overall Survival
KM 24 months
|
46.2 percentage surviving
Interval 33.8 to 57.7
|
—
|
SECONDARY outcome
Timeframe: 3 months from the completion of radiotherapyPopulation: Including those with 3 month follow up acute toxicity available. Frequency threshold for reporting: Renal and urinary symptom reported in 20% or more of patients with symptoms/toxicity reported.
Assessed by looking at change in symptom scores from pre to post radiotherapy. The number of patients with post-radiotherapy scores lower than their baseline score have been used to calculate the control rate of presenting symptoms and is presented separately for the two randomisation groups.
Outcome measures
| Measure |
Standard Planning
n=27 Participants
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
n=29 Participants
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
The Control Rate of Presenting Symptoms
Nocturia
|
3 participants
|
5 participants
|
|
The Control Rate of Presenting Symptoms
Frequency/Urgency
|
5 participants
|
7 participants
|
|
The Control Rate of Presenting Symptoms
Urinary incontinence
|
4 participants
|
4 participants
|
|
The Control Rate of Presenting Symptoms
Cystitis
|
3 participants
|
8 participants
|
|
The Control Rate of Presenting Symptoms
Haematuria
|
4 participants
|
8 participants
|
SECONDARY outcome
Timeframe: End of treatment, treatment is given over 6 weeksPopulation: ITT
Assessed by the number of small or large plans being selected rather than the medium plan for patients in the adaptive planning group. The denominator will be the total number of fractions received in the adaptive planning group.
Outcome measures
| Measure |
Standard Planning
n=193 Fractions
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
Adaptive Planning
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
|---|---|---|
|
The Proportion of Fractions Benefiting From Adaptive Planning
|
76 Fractions
|
—
|
Adverse Events
Adaptive Planning
Serious events: 9 serious events
Other events: 33 other events
Deaths: 0 deaths
Standard Planning
Serious events: 11 serious events
Other events: 32 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Adaptive Planning
n=33 participants at risk
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
Standard Planning
n=32 participants at risk
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Blood and lymphatic system disorders
Anaemia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood creatinine increased
|
12.1%
4/33 • Number of events 4 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood phosphorus decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood potassium increased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood sodium decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood urea increased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Bronchopneumonia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Cardiac disorders
Cardiac failure congestive
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Constipation
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Decreased appetite
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Dehydration
|
9.1%
3/33 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Diarrhoea
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
General disorders
Fatigue
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
6.1%
2/33 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
9.1%
3/33 • Number of events 4 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Nausea
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Reproductive system and breast disorders
Perineal pain
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Pneumonia
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal failure acute
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal failure chronic
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Sepsis
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Urinary tract infection
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Weight decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
Other adverse events
| Measure |
Adaptive Planning
n=33 participants at risk
Adaptive planning radiotherapy
Adaptive planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
|
Standard Planning
n=32 participants at risk
Standard planning radiotherapy
Standard planning radiotherapy: 36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
|
|---|---|---|
|
Gastrointestinal disorders
Abdominal pain
|
45.5%
15/33 • Number of events 42 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
40.6%
13/32 • Number of events 35 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Alanine aminotransferase increased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Blood and lymphatic system disorders
Anaemia
|
18.2%
6/33 • Number of events 13 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
25.0%
8/32 • Number of events 27 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Musculoskeletal and connective tissue disorders
Arthralgia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Aspartate aminotransferase increased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Musculoskeletal and connective tissue disorders
Back pain
|
3.0%
1/33 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
12.5%
4/32 • Number of events 11 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Bladder obstruction
|
21.2%
7/33 • Number of events 8 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
34.4%
11/32 • Number of events 34 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Bladder pain
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Bladder spasm
|
27.3%
9/33 • Number of events 17 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
46.9%
15/32 • Number of events 41 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood albumin decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood alkaline phosphatase increased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood bilirubin decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood creatinine increased
|
30.3%
10/33 • Number of events 28 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
43.8%
14/32 • Number of events 62 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood phosphorus decreased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 5 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood potassium increased
|
6.1%
2/33 • Number of events 4 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood sodium decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Blood urea increased
|
9.1%
3/33 • Number of events 13 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
9.4%
3/32 • Number of events 11 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Bronchopneumonia
|
6.1%
2/33 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Cardiac disorders
Cardiac failure congestive
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Cardiac disorders
Cardiorenal syndrome
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Cellulitis
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
General disorders and administration site conditions
Chills
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Psychiatric disorders
Confusional state
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Constipation
|
48.5%
16/33 • Number of events 58 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
68.8%
22/32 • Number of events 96 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Respiratory, thoracic and mediastinal disorders
Cough
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Cystitis
|
63.6%
21/33 • Number of events 77 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
65.6%
21/32 • Number of events 63 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Decreased appetite
|
48.5%
16/33 • Number of events 51 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
53.1%
17/32 • Number of events 57 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Dehydration
|
27.3%
9/33 • Number of events 34 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
18.8%
6/32 • Number of events 9 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Diarrhoea
|
66.7%
22/33 • Number of events 64 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
71.9%
23/32 • Number of events 50 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Nervous system disorders
Dizziness
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Dry mouth
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 5 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Respiratory, thoracic and mediastinal disorders
Dyspnoea
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Dysuria
|
12.1%
4/33 • Number of events 17 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 8 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Skin and subcutaneous tissue disorders
Erythema
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Faecal incontinence
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
General disorders and administration site conditions
Fatigue
|
93.9%
31/33 • Number of events 168 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
96.9%
31/32 • Number of events 188 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Frequent bowel movements
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Fungal infection
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Gamma-glutamyltransferase increased
|
6.1%
2/33 • Number of events 8 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 4 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Gastrointestinal fistula
|
6.1%
2/33 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Gastrointestinal haemorrhage
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Gastrointestinal obstruction
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Haematuria
|
48.5%
16/33 • Number of events 46 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
53.1%
17/32 • Number of events 44 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Injury, poisoning and procedural complications
Hip fracture
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Reproductive system and breast disorders
Hot flush
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Hydronephrosis
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hypercalcaemia
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hyperkalaemia
|
12.1%
4/33 • Number of events 7 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 6 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hypernatraemia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hyperuricaemia
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hypoglycaemia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hypokalaemia
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Metabolism and nutrition disorders
Hyponatraemia
|
9.1%
3/33 • Number of events 5 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 6 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Lower gastrointestinal haemorrhage
|
9.1%
3/33 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Lymphocyte count decreased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Vascular disorders
Lymphoedema
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Micturition disorder
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Micturition urgency
|
9.1%
3/33 • Number of events 4 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Musculoskeletal and connective tissue disorders
Mobility decreased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Musculoskeletal and connective tissue disorders
Muscular weakness
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Cardiac disorders
Myocardial infarction
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Nausea
|
24.2%
8/33 • Number of events 24 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
18.8%
6/32 • Number of events 14 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Neutrophil count increased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Nocturia
|
93.9%
31/33 • Number of events 209 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
87.5%
28/32 • Number of events 193 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
General disorders and administration site conditions
Non-cardiac chest pain
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Pelvic pain
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Reproductive system and breast disorders
Perineal pain
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Platelet count decreased
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Pneumonia
|
6.1%
2/33 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Pollakiuria
|
90.9%
30/33 • Number of events 182 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
87.5%
28/32 • Number of events 175 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Proctitis
|
15.2%
5/33 • Number of events 7 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
18.8%
6/32 • Number of events 9 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal colic
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal failure
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal failure acute
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Renal failure chronic
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Nervous system disorders
Restless legs syndrome
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 7 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Sepsis
|
6.1%
2/33 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Skin and subcutaneous tissue disorders
Skin lesion
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Urinary bladder adenoma
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Urinary hesitation
|
9.1%
3/33 • Number of events 12 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 2 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Urinary incontinence
|
57.6%
19/33 • Number of events 75 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
50.0%
16/32 • Number of events 62 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Urinary retention
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
9.4%
3/32 • Number of events 11 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Urinary tract infection
|
18.2%
6/33 • Number of events 12 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
12.5%
4/32 • Number of events 8 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Renal and urinary disorders
Urinary tract obstruction
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 4 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Infections and infestations
Urosepsis
|
3.0%
1/33 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
0.00%
0/32 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Gastrointestinal disorders
Vomiting
|
21.2%
7/33 • Number of events 11 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
6.2%
2/32 • Number of events 3 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
Weight decreased
|
27.3%
9/33 • Number of events 14 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
31.2%
10/32 • Number of events 24 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
|
Investigations
White blood cell count increased
|
0.00%
0/33 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
3.1%
1/32 • Number of events 1 • Adverse event data was collected up to 24 months.
Adverse event data were collected at the following timepoints: Baseline Acute toxicity: RT week1, RT week2, RT week3, RT week4, RT week5, RT week6, Post RT week4, Post RT 3M Late toxicity: 6M, 12M, 24M
|
Additional Information
Professor Emma Hall (Co-Director of ICR-CTSU)
The Institute of Cancer Research, Clinical Trials and Statistics Unit (ICR-CTSU)
Phone: +44 (0)208 722
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place